Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schultz Exits: Pressures From Inside And Out Catch Up With CDRH Director

This article was originally published in The Gray Sheet

Executive Summary

At least a handful of disgruntled employees, members of Congress champing at the bit and a new reformist FDA administration were apparently the undoing of Dan Schultz's leadership of CDRH

You may also be interested in...



Retiring Rep. Dingell’s Health Policy Legacy Includes Fierce Oversight Of Device Center

A powerful former Chairman of the House Energy and Commerce Committee, Dingell has been not only a major player in the health care reform fight, but also a vigorous prober of FDA, launching investigations with lasting effects on the device center. The longest-serving member of the House announced his plans to retire at the end of this congressional term.

Retiring Rep. Dingell’s Health Policy Legacy Included Fierce Oversight Of Device Center

A powerful former Chairman of the House Energy and Commerce Committee, Dingell has not been only a major player in the health care reform fight, but also a vigorous prober of FDA, launching investigations with lasting effects on the device center. The longest-serving member of the House announced his plans to retire at the end of this congressional term.

Director Of 510(k) Pre-Market Notification Staff Makes Her Exit

Heather Rosecrans, the long-time head of the 510(k) pre-market review section at FDA's device center, says it's time for her to move on

Related Content

Topics

UsernamePublicRestriction

Register

MT027800

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel